Craig Tooman, Silence Therapeutics CEO

Si­lence re­ports pos­i­tive PhII cho­les­terol drug da­ta, re­veals end to Mallinck­rodt al­liance

Si­lence Ther­a­peu­tics has re­port­ed its siR­NA drug can­di­date showed pos­i­tive re­sults in a mid-stage test of pa­tients with high low-den­si­ty lipopro­tein at risk of car­dio­vas­cu­lar events, hit­ting bench­marks set by some an­a­lysts.

The UK biotech al­so re­port­ed Wednes­day that Mallinck­rodt de­cid­ed to stop fur­ther de­vel­op­ment of com­ple­ment C3-tar­get­ing drug SLN501 af­ter Phase I com­ple­tion, ef­fec­tive­ly end­ing their part­ner­ship, ac­cord­ing to a sep­a­rate full-year earn­ings re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.